HC Wainwright Reiterates “Buy” Rating for DiaMedica Therapeutics (NASDAQ:DMAC)

DiaMedica Therapeutics (NASDAQ:DMAC)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 69.90% from the stock’s previous close.

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, August 16th.

DiaMedica Therapeutics Stock Down 3.3 %

Shares of NASDAQ:DMAC opened at $4.12 on Friday. The business has a fifty day simple moving average of $4.30 and a 200 day simple moving average of $3.56. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $4.95. The firm has a market cap of $176.13 million, a P/E ratio of -7.36 and a beta of 1.46.

Institutional Trading of DiaMedica Therapeutics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in DiaMedica Therapeutics by 26.3% during the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after purchasing an additional 211,351 shares during the period. Blue Trust Inc. acquired a new stake in shares of DiaMedica Therapeutics during the 3rd quarter worth approximately $185,000. Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the 2nd quarter valued at $87,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of DiaMedica Therapeutics in the 3rd quarter valued at $40,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.